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Therapy options for patients with advanced stage mela-
noma have improved steadily over the past decade, with
recent clinical successes noted for BRAF inhibitors
(BRAFi). BRAFi such as dabrafenib are highly specific
for BRAF mutant, BRAFV600E, which is expressed in
approximately 50% of melanomas. Although treatment
with BRAFi is highly efficacious with substantial tumor
regression and increased patient survival, the response is
short-lived, with treatment-refractory progressive disease
developing as early as six months. Refractory progressive
disease develops in association with tumor cell adoption
of alternate signaling pathways (linked to tumor cell
(over)expressed BRAFi-resistance associated molecules
(BRAFi-RAM) such as FGFR3, MEK, PDGFRb, SRC,
and STAT3, among others) supporting their continued
survival, growth, and metastatic potential. It is worth-
while noting that each of these molecules represents a
“client” protein of HSP90, a molecular chaperone com-
monly overexpressed in human melanomas where it
serves to post-translationally stabilize a broad range of
clients. Treatment of melanoma cells in vitro or in vivo
with HSP90 inhibitor (HSP90i), leads to the rapid pro-
teasome-dependent degradation of HSP90 client pro-
teins, with the resulting peptides used to load MHC
class I complexes on the tumor cell surface, thereby
conditionally-enhancing specific CD8+ T cell recogni-
tion. In this study, we hypothesize that specific vaccina-
tion against BRAFi-RAM in combination with systemic
HSP90i treatment will promote tumor regression and
increase overall survival in a BRAFi-resistant melanoma
mouse model. By treating with increasing concentrations
of dabrafenib, we have selected for and maintained a
dabrafenib-resistant BP (BRAFV600E; PTEN-/-) mouse
melanoma cell line (BPR20) that demonstrates upregula-
tion of BRAFi-RAM and increased activation of receptor
tyrosine kinase signaling pathways. Upregulated BRAFi-
RAM in BPR20 underwent proteasome-dependent
degradation when treated with ganetespib, an HSP90i.
Furthermore, a proportion of the upregulated BRAFi-
RAM were immunogenic. Specific CD8+ T cells were
generated when wild-type C57Bl/6 mice were vaccinated
with IL-12-expressing dendritic cells pulsed with a
BRAFi-RAM peptide pool, and those CD8+ T cells
demonstrated enhanced specific reactivity to syngeneic
cells presenting relevant antigen as revealed by IFNg
release assays. These results suggest that a polyepitope
vaccine based on BRAFi-resistance associated HSP90 cli-
ent proteins could define a novel immunotherapeutic
strategy for the (co)treatment of patients with advanced-
stage melanomas.
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